ImaginAb, Inc. U.S.

ImaginAb, Inc. is a biotechnology company based in the U. S. that specializes in advanced imaging technologies aimed at enhancing cancer immunotherapy through innovative solutions.

Founded in 2007 in Inglewood, US, ImaginAb, Inc. focuses on advanced imaging solutions for oncology, specifically through its flagship product. The company has raised a total of USD 12. 80 mn, with the latest funding round, a Growth round, occurring in January 2025, involving investors such as Adage Capital Management and Theravance, Inc.

ImaginAb has been involved in 9 notable deals throughout its history. ImaginAb’s core product is its advanced imaging agent, 89Zr crefmirlimab berdoxam, branded as CD8 ImmunoPET™, which enhances visualization of CD8 T-cells in oncology. This innovative technology employs 'minibody' antibodies for a comprehensive assessment of patients' immune status during immunotherapy, allowing healthcare providers and oncologists to optimize cancer treatment strategies across North America, Europe, and parts of Asia. ImaginAb generates revenue through partnerships and collaborations with healthcare providers and pharmaceutical companies that utilize its CD8 ImmunoPET™ technology.

The revenue stems from licensing agreements and collaborative research contracts, supporting clinical applications in oncology. The imaging services offered contribute significantly to advancing immunotherapy, although specific pricing structures are not publicly disclosed. In January 2025, Telix Pharmaceuticals Limited is set to acquire ImaginAb, Inc. to enhance its CD8 ImmunoPET technology currently in Phase 2 clinical trials.

This acquisition aims to accelerate the development of its prostate cancer imaging agent and strengthen its market position. The recent funding will support these initiatives as the company plans to expand its reach and influence in the oncology sector.